Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
- U.S. Clinical Sites Screening Treatment-Experienced Participants with Wet AMD - - ODYSSEY Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., June 01, 2023 -- Clearside Biomedical,... | June 1, 2023